Compare Becton Dickinson and Co (BDX) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs TeraWulf Inc — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while TeraWulf Inc trades at $17.37 (market cap $8.08B). The key difference: Becton Dickinson and Co is far larger — about 6.1× TeraWulf Inc's market cap, and Becton Dickinson and Co pays a 2.34% dividend while TeraWulf Inc pays none. Which is the better fit depends on your goals.
| BDX | WULF | |
|---|---|---|
Market Cap | $48.93B | $8.08B |
Sector | Health | Technology |
52-Week High | $185.39 | $28.98 |
52-Week Low | $138.62 | $5.24 |
Enterprise Value | $65.03B | $10.70B |
Dividend Yield | 2.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
TeraWulf (WULF) trades at $17.08, down 3.04% on the day, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $165M but a significant net loss of -$1.9B, reflecting a profit margin of -1,179.95%. Despite negative profitability metrics, all 14 analysts maintain Buy ratings with a $38 consensus price target, citing growth potential from AI infrastructure expansion including a major Anthropic lease.
The stock presents a high-risk, high-reward opportunity with strong Wall Street conviction despite fundamental challenges. Key catalysts include the AI pivot and capacity expansion, but investors face substantial execution risks, capital requirements, and ongoing losses that could pressure the stock near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
